Save your seat

Speaker detail

  • Kenneth I. Maynard
  • Global Patient Safety Evaluation (GPSE) Head, GPSE Compliance, Standards and Training, GPSE Business Partners Relations
  • Takeda

Kenneth I. Maynard, PhD, FAHA is a neuroscientist recently appointed as the Head of Global Pharmacovigilance Compliance, Standards and Training and PV Business Partners Relations at Takeda Pharmaceuticals, Inc. He was formerly Global Program Leader and then Portfolio Strategy Lead in the Central Nervous System Therapeutic Area Unit at Takeda which he joined in 2014. From 2000 to 2014, Dr. Maynard held the positions of Section Head, Cerebrovascular Disorders, CNS Drug Discovery (Aventis), Project Director, Neurology (Sanofi-Aventis) and Global Head, External Innovation, Therapeutic Strategy Unit, Aging at Sanofi. He earned his BSc, MSc, and PhD degrees at University College, London, UK from 1983 to 1991 and transitioned from his first postdoctoral position to Assistant Professor in Surgery (Neurosurgery) and Assistant Neuroscientist at Massachusetts. General Hospital and Harvard Medical School from 1991 to 2000. Having more than 50 scientific publications, Dr. Maynard serves on two international journals’ editorial boards, is a fellow of the American Heart Association, councilor for the Society for Neuroscience, serves on the Executive Committee of the International Dose-Response Society, the External Scientific Panel of the NIH Program on Broadening Experiences in Scientific Training and the National Academy of Sciences Next Generation Researchers Initiative committee.